8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Mar 30, 2026·SEC
Pliant Therapeutics, Inc.(PLRX)Earnings, Financials & Key Ratios
PLRX•NASDAQ
Price updated Jun 13, 2026
AboutPliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$148M+34.4%
- Net Income-$149M+29.0%
- EPS (Diluted)-2.43+30.0%
- ROE-61.55%-13.8%
- ROIC-49.16%-2.6%
- Debt/Equity0.16-18.9%
- Interest Coverage-58.65+14.4%
PLRX Key Insights
Pliant Therapeutics, Inc. (PLRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Profits declining 29.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PLRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PLRX Price & Volume
Pliant Therapeutics, Inc. (PLRX) stock price & volume — 10-year historical chart
Loading chart...
PLRX Growth Metrics
Pliant Therapeutics, Inc. (PLRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM48.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.03%
Return on Capital
10 Years-100.31%
5 Years-47.92%
3 Years-50.59%
Last Year-52.42%
PLRX Recent Earnings
Pliant Therapeutics, Inc. (PLRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 11, 2026EPS
$0.32
Est $0.36
+11.1%
Revenue
—
Q2 2026
Mar 11, 2026EPS
$0.35
Est $0.42
+16.7%
Revenue
—
Est $5M
Q4 2025
Nov 6, 2025EPS
$0.43
Est $0.53
+18.9%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.71
Est $0.62
-14.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.32vs $0.36+11.1% | — |
| Q2 2026 | Mar 11, 2026 | $0.35vs $0.42+16.7% | —vs $5M |
| Q4 2025 | Nov 6, 2025 | $0.43vs $0.53+18.9% | — |
| Q3 2025 | Aug 7, 2025 | $0.71vs $0.62-14.5% | — |
Based on last 12 quarters of dataView full earnings history →
PLRX Peer Comparison
Pliant Therapeutics, Inc. (PLRX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GILD | 155.93B | 125.59 | 18.52 | 2.39% | 30.99% | 42.33% | 1.09 | |
 IDYA | 2.55B | 28.98 | -22.64 | 30.24% | -62.17% | -13.96% | 0.03 | |
 HALO | 8.24B | 69.50 | 27.15 | 37.55% | 23.13% | 126.27% | 43.89 | |
 AKBA | 248M | 0.92 | -44.45 | 47.46% | -8.83% | -62.72% | 6.63 | |
 INVA | 1.68B | 22.74 | 6.89 | 18.52% | 118.91% | 47.59% | 0.23 | |
 MDGL | 11.08B | 480.77 | -37.41 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HIMS | 5.89B | 26.82 | 52.59 | 59% | -0.56% | -2.48% | 2.34 |
Compare PLRX vs Peers
Pliant Therapeutics, Inc. (PLRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PLRX Income Statement
Pliant Therapeutics, Inc. (PLRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 57.05M | 41.82M | 7.57M | 9.69M | 1.58M | 0 | 0 | 0 |
Revenue Growth % | - | - | - | -26.7% | -81.89% | 27.91% | -83.69% | -100% | - | - |
Cost of Goods Sold | 0 | 666K | 0 | 0 | 0 | 0 | 0 | 0 | 1.7M | 711K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | -666K▲ 0% | 57.05M▲ 8666.4% | 41.82M▼ 26.7% | 7.57M▼ 81.9% | 9.69M▲ 27.9% | 1.58M▼ 83.7% | 0▼ 100.0% | -1.7M▲ 0% | -711K▲ 0% |
Gross Margin % | - | - | 100% | 100% | 100% | 100% | 100% | - | - | - |
Gross Profit Growth % | - | - | 8666.37% | -26.7% | -81.89% | 27.91% | -83.69% | -100% | - | - |
Operating Expenses | 18.35M | 30.91M | 58.28M | 83.46M | 105.11M | 136.88M | 185.72M | 228.37M | 148.38M | 118.5M |
OpEx % of Revenue | - | - | 102.16% | 199.59% | 1388.1% | 1413.37% | 11754.75% | - | - | - |
Selling, General & Admin | 3.82M | 6.5M | 10.93M | 17.27M | 27.56M | 39.95M | 57.93M | 59.05M | 47.22M | 39.91M |
SG&A % of Revenue | - | - | 19.16% | 41.3% | 363.95% | 412.48% | 3666.33% | - | - | - |
Research & Development | 14.53M | 24.41M | 47.35M | 66.19M | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M | 79.04M |
R&D % of Revenue | - | - | 83% | 158.29% | 1024.15% | 1000.89% | 8088.42% | - | - | - |
Other Operating Expenses | 0 | -49K | 0 | 0 | 0 | 0 | 0 | 0 | -8M | -447K |
Operating Income | -18.35M▲ 0% | -30.91M▼ 68.5% | -1.23M▲ 96.0% | -41.65M▼ 3283.0% | -97.53M▼ 134.2% | -127.2M▼ 30.4% | -184.15M▼ 44.8% | -228.37M▼ 24.0% | -150.07M▲ 34.3% | -119.21M▲ 0% |
Operating Margin % | - | - | -2.16% | -99.59% | -1288.1% | -1313.37% | -11654.75% | - | - | - |
Operating Income Growth % | - | -68.48% | 96.02% | -3283.02% | -134.21% | -30.41% | -44.77% | -24.01% | 34.28% | - |
EBITDA | -18.06M | -30.25M | -118K | -40.34M | -96M | -123.52M | -182.3M | -226.24M | -148.38M | -117.7M |
EBITDA Margin % | - | - | -0.21% | -96.46% | -1267.83% | -1275.36% | -11538.23% | - | - | - |
EBITDA Growth % | - | -67.52% | 99.61% | -34082.2% | -138.01% | -28.67% | -47.59% | -24.1% | 34.42% | 49.45% |
D&A (Non-Cash Add-back) | 292K | 666K | 1.11M | 1.31M | 1.53M | 3.68M | 1.84M | 2.13M | 1.7M | 1.51M |
EBIT | -18.35M | -30.91M | -1.23M | -41.65M | -97.26M | -122.53M | -160.07M | -207.28M | -150.07M | -111.22M |
Net Interest Income | 0 | 0 | 600K | 112K | 272K | 3.88M | 22.81M | 18.06M | -2.56M | 1.34M |
Interest Income | 16K | 688K | 816K | 478K | 272K | 4.67M | 24.08M | 21.09M | 0 | 5.07M |
Interest Expense | 0 | 0 | 216K | 366K | 0 | 791K | 1.27M | 3.02M | 2.56M | 3.73M |
Other Income/Expense | 16K | 639K | 600K | 112K | 272K | 3.88M | 22.81M | 18.06M | 729K | 5.99M |
Pretax Income | -18.33M▲ 0% | -30.28M▼ 65.1% | -631K▲ 97.9% | -41.53M▼ 6482.1% | -97.26M▼ 134.2% | -123.32M▼ 26.8% | -161.34M▼ 30.8% | -210.3M▼ 30.4% | -149.34M▲ 29.0% | -113.22M▲ 0% |
Pretax Margin % | - | - | -1.11% | -99.32% | -1284.51% | -1273.32% | -10211.14% | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -20.62M▲ 0% | -30.28M▼ 46.8% | -631K▲ 97.9% | -41.53M▼ 6482.1% | -97.26M▼ 134.2% | -123.32M▼ 26.8% | -161.34M▼ 30.8% | -210.3M▼ 30.4% | -149.34M▲ 29.0% | -113.22M▲ 0% |
Net Margin % | - | - | -1.11% | -99.32% | -1284.51% | -1273.32% | -10211.14% | - | - | - |
Net Income Growth % | - | -46.81% | 97.92% | -6482.09% | -134.18% | -26.79% | -30.83% | -30.35% | 28.99% | 48.42% |
Net Income (Continuing) | -18.33M | -30.28M | -631K | -41.53M | -97.26M | -123.32M | -161.34M | -210.3M | -149.34M | -113.22M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -25.67▲ 0% | -1.83▲ 92.9% | 0.01▲ 100.3% | -1.17▼ 22600.0% | -2.71▼ 131.6% | -2.94▼ 8.5% | -2.75▲ 6.5% | -3.47▼ 26.2% | -2.43▲ 30.0% | -1.83▲ 0% |
EPS Growth % | - | 92.87% | 100.28% | - | -131.62% | -8.49% | 6.46% | -26.18% | 29.97% | 49.03% |
EPS (Basic) | -25.67 | -1.83 | 0.01 | -1.17 | -2.71 | -2.94 | -2.75 | -3.47 | -2.43 | - |
Diluted Shares Outstanding | 803.5K | 16.51M | 35.55M | 35.55M | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M | 61.8M |
Basic Shares Outstanding | 803.5K | 16.51M | 35.55M | 35.55M | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M | 61.8M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PLRX Balance Sheet
Pliant Therapeutics, Inc. (PLRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 4.71M | 61.73M | 111.9M | 290.75M | 209.44M | 340.31M | 505.5M | 362.26M | 196.45M | 174.93M |
Cash & Short-Term Investments | 4.25M | 60.95M | 102.77M | 276.89M | 200.6M | 331.19M | 494.25M | 355.72M | 190.94M | 170.89M |
Cash Only | 4.25M | 60.95M | 85.81M | 50.88M | 51.66M | 33.69M | 63.23M | 71.19M | 45.45M | 22.19M |
Short-Term Investments | 0 | 0 | 16.97M | 226.01M | 148.93M | 297.5M | 431.01M | 284.54M | 145.5M | 148.7M |
Accounts Receivable | 0 | 500K | 7.38M | 9.36M | 2.47M | 3.14M | 3M | 2.3M | 823K | 914K |
Days Sales Outstanding | - | - | 47.25 | 81.72 | 118.87 | 118.49 | 692.34 | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 250K | 0 | 0 | 0 | 156K | 173K | 1.27M | 163K | 4.68M | 3.12M |
Total Non-Current Assets | 1.85M | 4.8M | 7.16M | 4.77M | 11.77M | 10.3M | 6.65M | 34.69M | 28.78M | 27.67M |
Property, Plant & Equipment | 1.85M | 4.26M | 4.08M | 4.32M | 10.94M | 9.91M | 4.78M | 32.77M | 25.01M | 24.04M |
Fixed Asset Turnover | - | - | 13.99x | 9.68x | 0.69x | 0.98x | 0.33x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 536K | 3.08M | 451K | 838K | 394K | 1.87M | 1.92M | 3.77M | 3.63M |
Total Assets | 6.55M▲ 0% | 66.53M▲ 915.2% | 119.06M▲ 79.0% | 295.53M▲ 148.2% | 221.22M▼ 25.1% | 350.61M▲ 58.5% | 512.15M▲ 46.1% | 396.95M▼ 22.5% | 225.23M▼ 43.3% | 202.6M▲ 0% |
Asset Turnover | - | - | 0.48x | 0.14x | 0.03x | 0.03x | 0.00x | - | - | 0.00x |
Asset Growth % | - | 915.24% | 78.97% | 148.21% | -25.15% | 58.49% | 46.07% | -22.49% | -43.26% | -160.45% |
Total Current Liabilities | 3.19M | 5.08M | 8.17M | 11.6M | 16.83M | 23.91M | 28.52M | 33.22M | 16.36M | 10.36M |
Accounts Payable | 1.59M | 2.58M | 1.25M | 2.02M | 2.97M | 1.58M | 4.53M | 5.96M | 480K | 362K |
Days Payables Outstanding | - | 1.41K | - | - | - | - | - | - | 103.3 | 347.93 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 130K | 3.04M | 4.63M | 5.22M | 7.2M | 9.04M | 0 | 14.44M | 8.28M |
Current Ratio | 1.48x | 12.14x | 13.69x | 25.07x | 12.44x | 14.23x | 17.72x | 10.91x | 12.00x | 16.89x |
Quick Ratio | 1.48x | 12.14x | 13.69x | 25.07x | 12.44x | 14.23x | 17.72x | 10.91x | 12.00x | 16.89x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 62.33M | 111.33M | 866K | 5.33M | 13.36M | 10.05M | 59.65M | 27.66M | 27.07M |
Long-Term Debt | 0 | 525K | 0 | 0 | 0 | 9.93M | 10.05M | 30.21M | 0 | 0 |
Capital Lease Obligations | 0 | 525K | 444K | 0 | 5.33M | 3.43M | 0 | 29.44M | 27.66M | 111.75M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 61.28M | 110.88M | 866K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.19M | 67.41M | 119.5M | 12.46M | 22.16M | 37.27M | 38.58M | 92.87M | 44.02M | 37.43M |
Total Debt | 0 | 525K | 444K | 0 | 7.19M | 15.81M | 11.37M | 60.19M | 29.11M | 28.78M |
Net Debt | -4.25M | -60.42M | -85.36M | -50.88M | -44.47M | -17.87M | -51.86M | -11M | -16.34M | 6.59M |
Debt / Equity | - | - | - | - | 0.04x | 0.05x | 0.02x | 0.20x | 0.16x | 0.17x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.24x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
Interest Coverage | - | - | -5.70x | -113.78x | - | -154.91x | -126.34x | -68.54x | -58.65x | -29.83x |
Total Equity | 3.35M▲ 0% | -882K▼ 126.4% | -435K▲ 50.7% | 283.06M▲ 65171.5% | 199.06M▼ 29.7% | 313.34M▲ 57.4% | 473.58M▲ 51.1% | 304.08M▼ 35.8% | 181.21M▼ 40.4% | 165.17M▲ 0% |
Equity Growth % | - | -126.37% | 50.68% | 65171.49% | -29.68% | 57.41% | 51.14% | -35.79% | -40.41% | -162.22% |
Book Value per Share | 4.16 | -0.05 | -0.01 | 7.96 | 5.55 | 7.46 | 8.07 | 5.02 | 2.95 | 2.67 |
Total Shareholders' Equity | 3.35M | -882K | -435K | 283.06M | 199.06M | 313.34M | 473.58M | 304.08M | 181.21M | 165.17M |
Common Stock | 1K | 1K | 1K | 3K | 3K | 5K | 6K | 6K | 6K | 6K |
Retained Earnings | -36.57M | -71.47M | -76.3M | -117.83M | -215.09M | -338.41M | -499.75M | -710.05M | -859.4M | -879.44M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -1.07M | -1K | -32K | -201K | -1.96M | 345K | 321K | -15K | -341K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PLRX Cash Flow Statement
Pliant Therapeutics, Inc. (PLRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -16.92M | -28.33M | -2.75M | -37.27M | -75.44M | -94.63M | -116.36M | -155.5M | -128.34M | -98.7M |
Operating CF Margin % | - | - | -4.82% | -89.13% | -996.34% | -977.09% | -7364.62% | - | - | - |
Operating CF Growth % | - | -67.38% | 90.29% | -1255.31% | -102.42% | -25.43% | -22.96% | -33.64% | 17.47% | 168.37% |
Net Income | -18.33M | -30.28M | -631K | -41.53M | -97.26M | -123.32M | -161.34M | -210.3M | -149.34M | -113.22M |
Depreciation & Amortization | 292K | 666K | 1.11M | 1.31M | 1.53M | 1.82M | 1.84M | 2.13M | 1.7M | 1.51M |
Stock-Based Compensation | 33K | 228K | 1.83M | 3.9M | 10.44M | 22.6M | 44.48M | 37.63M | 26.23M | 10.9M |
Deferred Taxes | 0 | 0 | -12.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 191K | 1.05M | 12.2M | 266K | 2.93M | 52K | -2.6M | 5.96M | 9.02M | 18.67M |
Working Capital Changes | 893K | 1.05M | -5.06M | -1.21M | 6.92M | 4.22M | 1.25M | 9.09M | -15.94M | -16.57M |
Change in Receivables | 0 | -250K | -7.05M | -2.23M | 7.28M | 15K | 1.98M | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 3.2M | 113K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 760K | -1.25M | 922K | 891K | -1.35M | 2.97M | 1.43M | -5.48M | -5.26M |
Cash from Investing | -1.41M | -2.32M | -17.93M | -210.87M | 73.7M | -150.2M | -127.01M | 140.34M | 134.29M | 61.08M |
Capital Expenditures | -1.41M | -2.32M | -964K | -1.53M | -1.95M | -1.76M | -921K | -3.85M | -374K | 44K |
CapEx % of Revenue | - | - | 1.69% | 3.66% | 25.79% | 18.17% | 58.29% | - | - | - |
Acquisitions | 0 | 0 | 254K | 209.33M | -75.65M | 148.44M | 0 | 0 | 155K | 102K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -254K | -209.33M | 75.65M | -148.44M | 0 | 0 | 0 | -1K |
Cash from Financing | 20.01M | 87.35M | 45.54M | 213.21M | 2.53M | 226.85M | 274.4M | 23.12M | -31.7M | -32.12M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 10M | 0 | 19.91M | -32.27M | -32.27M |
Equity Issued (Net) | -12K | 0 | 48.12M | 213.21M | 2.98M | 215.64M | 269.4M | 3.21M | 570K | 146K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 20.02M | 87.35M | -2.58M | 0 | -457K | 1.21M | 5M | 0 | 0 | 0 |
Net Change in Cash | 1.68M▲ 0% | 56.7M▲ 3280.9% | 24.86M▼ 56.2% | -34.92M▼ 240.5% | 783K▲ 102.2% | -17.98M▼ 2396.4% | 31.03M▲ 272.6% | 7.95M▼ 74.4% | -25.74M▼ 423.6% | -69.75M▲ 0% |
Free Cash Flow | -18.33M▲ 0% | -30.65M▼ 67.2% | -3.71M▲ 87.9% | -38.8M▼ 944.8% | -77.4M▼ 99.5% | -96.39M▼ 24.5% | -117.28M▼ 21.7% | -159.35M▼ 35.9% | -128.71M▲ 19.2% | -98.81M▲ 0% |
FCF Margin % | - | - | -6.51% | -92.79% | -1022.13% | -995.26% | -7422.91% | - | - | - |
FCF Growth % | - | -67.23% | 87.88% | -944.78% | -99.46% | -24.54% | -21.67% | -35.87% | 19.23% | 44.08% |
FCF per Share | -22.81 | -1.86 | -0.10 | -1.09 | -2.16 | -2.29 | -2.00 | -2.63 | -2.10 | -1.60 |
FCF Conversion (FCF/Net Income) | 0.82x | 0.94x | 4.36x | 0.90x | 0.78x | 0.77x | 0.72x | 0.74x | 0.86x | 0.87x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.47M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PLRX Key Ratios
Pliant Therapeutics, Inc. (PLRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -2458.47% | - | -29.39% | -40.35% | -48.13% | -41% | -54.09% | -61.55% | -59.06% |
| Return on Invested Capital (ROIC) | - | - | -42.67% | -37.83% | -42.39% | -38.51% | -47.92% | -49.16% | -51.33% |
| Gross Margin | - | 100% | 100% | 100% | 100% | 100% | - | - | - |
| Net Margin | - | -1.11% | -99.32% | -1284.51% | -1273.32% | -10211.14% | - | - | - |
| Debt / Equity | - | - | - | 0.04x | 0.05x | 0.02x | 0.20x | 0.16x | 0.17x |
| Interest Coverage | - | -5.70x | -113.78x | - | -154.91x | -126.34x | -68.54x | -58.65x | -29.83x |
| FCF Conversion | 0.94x | 4.36x | 0.90x | 0.78x | 0.77x | 0.72x | 0.74x | 0.86x | 0.87x |
| Revenue Growth | - | - | -26.7% | -81.89% | 27.91% | -83.69% | -100% | - | - |
Related:PLRX Dividend History·PLRX Revenue History·PLRX Price History·PLRX P/E History·PLRX Financial Ratios·PLRX Institutional Holders
PLRX SEC Filings & Documents
Pliant Therapeutics, Inc. (PLRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
PLRX Frequently Asked Questions
Pliant Therapeutics, Inc. (PLRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pliant Therapeutics, Inc. (PLRX) grew revenue by 0.0% over the past year. Growth has been modest.
Pliant Therapeutics, Inc. (PLRX) reported a net loss of $113.2M for fiscal year 2025.
Dividend & Returns
Pliant Therapeutics, Inc. (PLRX) has a return on equity (ROE) of -61.5%. Negative ROE indicates the company is unprofitable.
Pliant Therapeutics, Inc. (PLRX) had negative free cash flow of $98.8M in fiscal year 2025, likely due to heavy capital investments.